Research translation and personalized medicine

Research output: Chapter in Book/Report/Conference proceedingChapter

7 Citations (Scopus)

Abstract

The convergence of technological advances leading to affordable genome sequencing and an ever increasing arsenal of molecularly targeted drugs are revolutionizing oncology. These developments set the foundation for personalized cancer therapy, a tailored approach to cancer treatment that exploits precise knowledge about molecular alterations in tumors. This chapter contextualizes these developments and discusses their implications and practical applications for renal cancer. At the outset, two cases are presented in which information about the molecular genetics of the tumor impacted patient management. These cases illustrate the challenges and opportunities associated with this approach. Precedent was set by the identification of mutations in the VHL gene and the implication of the mTORC1 in renal cancer. Recent advances have begun to unravel the complex interplay between pVHL and mTORC1 pathways and have uncovered a role of mTORC1 in the regulation, not only of protein translation and cell growth but also of sequence-specific transcription factors and gene expression. mTOR remains an important therapeutic target, and catalytic inhibitors targeting both mTORC1 and mTORC2 as well as PI3K isoforms are under evaluation. Opportunities are emerging from cancer genome/exome sequencing studies. Mutations create vulnerabilities that can be exploited with chemical-genetic screens. Drug development may be accelerated with improved preclinical models that accurately reproduce the molecular genetics and treatment responsiveness of RCC in patients. Renewed emphasis is needed on correlative studies in clinical trials. A vision is presented for an integrated research translation program for the advancement of personalized genomic-based cancer medicine.

Original languageEnglish (US)
Title of host publicationRenal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets
PublisherSpringer US
Pages161-191
Number of pages31
Volume9781461424000
ISBN (Print)9781461424000, 1461423996, 9781461423997
DOIs
StatePublished - Nov 1 2012

Fingerprint

Precision Medicine
Research
Neoplasms
Kidney Neoplasms
Molecular Biology
Genome
Exome
Mutation
Protein Biosynthesis
Therapeutics
Phosphatidylinositol 3-Kinases
Pharmaceutical Preparations
Protein Isoforms
Transcription Factors
Medicine
Clinical Trials
Gene Expression
mechanistic target of rapamycin complex 1
Growth
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Brugarolas, J. (2012). Research translation and personalized medicine. In Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets (Vol. 9781461424000, pp. 161-191). Springer US. https://doi.org/10.1007/978-1-4614-2400-0_8

Research translation and personalized medicine. / Brugarolas, James.

Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. Vol. 9781461424000 Springer US, 2012. p. 161-191.

Research output: Chapter in Book/Report/Conference proceedingChapter

Brugarolas, J 2012, Research translation and personalized medicine. in Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. vol. 9781461424000, Springer US, pp. 161-191. https://doi.org/10.1007/978-1-4614-2400-0_8
Brugarolas J. Research translation and personalized medicine. In Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. Vol. 9781461424000. Springer US. 2012. p. 161-191 https://doi.org/10.1007/978-1-4614-2400-0_8
Brugarolas, James. / Research translation and personalized medicine. Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. Vol. 9781461424000 Springer US, 2012. pp. 161-191
@inbook{b244630d69284dcdbf5b9107d1836987,
title = "Research translation and personalized medicine",
abstract = "The convergence of technological advances leading to affordable genome sequencing and an ever increasing arsenal of molecularly targeted drugs are revolutionizing oncology. These developments set the foundation for personalized cancer therapy, a tailored approach to cancer treatment that exploits precise knowledge about molecular alterations in tumors. This chapter contextualizes these developments and discusses their implications and practical applications for renal cancer. At the outset, two cases are presented in which information about the molecular genetics of the tumor impacted patient management. These cases illustrate the challenges and opportunities associated with this approach. Precedent was set by the identification of mutations in the VHL gene and the implication of the mTORC1 in renal cancer. Recent advances have begun to unravel the complex interplay between pVHL and mTORC1 pathways and have uncovered a role of mTORC1 in the regulation, not only of protein translation and cell growth but also of sequence-specific transcription factors and gene expression. mTOR remains an important therapeutic target, and catalytic inhibitors targeting both mTORC1 and mTORC2 as well as PI3K isoforms are under evaluation. Opportunities are emerging from cancer genome/exome sequencing studies. Mutations create vulnerabilities that can be exploited with chemical-genetic screens. Drug development may be accelerated with improved preclinical models that accurately reproduce the molecular genetics and treatment responsiveness of RCC in patients. Renewed emphasis is needed on correlative studies in clinical trials. A vision is presented for an integrated research translation program for the advancement of personalized genomic-based cancer medicine.",
author = "James Brugarolas",
year = "2012",
month = "11",
day = "1",
doi = "10.1007/978-1-4614-2400-0_8",
language = "English (US)",
isbn = "9781461424000",
volume = "9781461424000",
pages = "161--191",
booktitle = "Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets",
publisher = "Springer US",

}

TY - CHAP

T1 - Research translation and personalized medicine

AU - Brugarolas, James

PY - 2012/11/1

Y1 - 2012/11/1

N2 - The convergence of technological advances leading to affordable genome sequencing and an ever increasing arsenal of molecularly targeted drugs are revolutionizing oncology. These developments set the foundation for personalized cancer therapy, a tailored approach to cancer treatment that exploits precise knowledge about molecular alterations in tumors. This chapter contextualizes these developments and discusses their implications and practical applications for renal cancer. At the outset, two cases are presented in which information about the molecular genetics of the tumor impacted patient management. These cases illustrate the challenges and opportunities associated with this approach. Precedent was set by the identification of mutations in the VHL gene and the implication of the mTORC1 in renal cancer. Recent advances have begun to unravel the complex interplay between pVHL and mTORC1 pathways and have uncovered a role of mTORC1 in the regulation, not only of protein translation and cell growth but also of sequence-specific transcription factors and gene expression. mTOR remains an important therapeutic target, and catalytic inhibitors targeting both mTORC1 and mTORC2 as well as PI3K isoforms are under evaluation. Opportunities are emerging from cancer genome/exome sequencing studies. Mutations create vulnerabilities that can be exploited with chemical-genetic screens. Drug development may be accelerated with improved preclinical models that accurately reproduce the molecular genetics and treatment responsiveness of RCC in patients. Renewed emphasis is needed on correlative studies in clinical trials. A vision is presented for an integrated research translation program for the advancement of personalized genomic-based cancer medicine.

AB - The convergence of technological advances leading to affordable genome sequencing and an ever increasing arsenal of molecularly targeted drugs are revolutionizing oncology. These developments set the foundation for personalized cancer therapy, a tailored approach to cancer treatment that exploits precise knowledge about molecular alterations in tumors. This chapter contextualizes these developments and discusses their implications and practical applications for renal cancer. At the outset, two cases are presented in which information about the molecular genetics of the tumor impacted patient management. These cases illustrate the challenges and opportunities associated with this approach. Precedent was set by the identification of mutations in the VHL gene and the implication of the mTORC1 in renal cancer. Recent advances have begun to unravel the complex interplay between pVHL and mTORC1 pathways and have uncovered a role of mTORC1 in the regulation, not only of protein translation and cell growth but also of sequence-specific transcription factors and gene expression. mTOR remains an important therapeutic target, and catalytic inhibitors targeting both mTORC1 and mTORC2 as well as PI3K isoforms are under evaluation. Opportunities are emerging from cancer genome/exome sequencing studies. Mutations create vulnerabilities that can be exploited with chemical-genetic screens. Drug development may be accelerated with improved preclinical models that accurately reproduce the molecular genetics and treatment responsiveness of RCC in patients. Renewed emphasis is needed on correlative studies in clinical trials. A vision is presented for an integrated research translation program for the advancement of personalized genomic-based cancer medicine.

UR - http://www.scopus.com/inward/record.url?scp=84936987707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936987707&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-2400-0_8

DO - 10.1007/978-1-4614-2400-0_8

M3 - Chapter

SN - 9781461424000

SN - 1461423996

SN - 9781461423997

VL - 9781461424000

SP - 161

EP - 191

BT - Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets

PB - Springer US

ER -